Hypertension in Pheochromocytoma and Paraganglioma: Evaluation and Management in Pediatric Patients

Curr Hypertens Rep. 2021 May 27;23(5):32. doi: 10.1007/s11906-021-01150-9.

Abstract

Purpose of review: The rare catecholamine-secreting tumors, pheochromocytomas and paragangliomas (PPGL), account for a minority of cases of secondary hypertension in pediatrics. As such, perioperative blood pressure (BP) management in pediatric patients presents a distinct challenge. This review will expand the practitioner's knowledge of antihypertensive treatment options for the pediatric patient with PPGL with a focus on literature in the past several years.

Recent findings: There continue to be only small case series and single-center experiences to provide guidelines regarding BP management. While phenoxybenzamine has been more routinely used, selective α1-blockers, such as doxazosin, as well as calcium channel blockers, have also been utilized with success in pediatric patients. While the concept of obligatory α-adrenergic blockade for adult patients has been recently challenged, international guidelines and current practice patterns among pediatric clinicians continue to support preoperative α-adrenergic blockade to ensure the best possible patient outcomes. Selective α1-blockers and calcium channel blockers are becoming more commonly used given the high cost, limited availability, and undesirable side effect profile of phenoxybenzamine.

Keywords: Amlodipine; Doxazosin; Hypertension; Paragangliomas (PGL); Pediatrics; Pheochromocytomas (PCC).

Publication types

  • Review

MeSH terms

  • Adrenal Gland Neoplasms*
  • Adrenergic alpha-Antagonists
  • Adult
  • Child
  • Humans
  • Hypertension*
  • Paraganglioma*
  • Pediatrics*
  • Pheochromocytoma*

Substances

  • Adrenergic alpha-Antagonists